Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Sells $12,039.84 in Stock

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) CFO Keith A. Goldan sold 1,296 shares of the company's stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $9.29, for a total value of $12,039.84. Following the completion of the transaction, the chief financial officer owned 92,450 shares of the company's stock, valued at $858,860.50. The trade was a 1.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Syndax Pharmaceuticals Price Performance

NASDAQ SNDX traded down $0.21 on Friday, hitting $9.46. 1,900,856 shares of the company were exchanged, compared to its average volume of 1,863,707. Syndax Pharmaceuticals, Inc. has a 1-year low of $8.58 and a 1-year high of $25.07. The firm has a 50 day moving average of $9.91 and a two-hundred day moving average of $12.21. The company has a current ratio of 5.80, a quick ratio of 5.75 and a debt-to-equity ratio of 1.53. The company has a market cap of $814.03 million, a P/E ratio of -2.45 and a beta of 0.70.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.04) by $0.06. Syndax Pharmaceuticals had a negative net margin of 757.53% and a negative return on equity of 101.60%. The company had revenue of $20.04 million for the quarter, compared to the consensus estimate of $15.88 million. During the same period in the prior year, the company posted ($0.85) EPS. The company's revenue was up 1900.0% compared to the same quarter last year. On average, equities analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on SNDX shares. Guggenheim restated a "buy" rating and issued a $32.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, May 6th. UBS Group dropped their price target on shares of Syndax Pharmaceuticals from $37.00 to $35.00 and set a "buy" rating for the company in a research report on Tuesday. Scotiabank raised their price target on shares of Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a "sector perform" rating in a research note on Tuesday, May 6th. JPMorgan Chase & Co. upped their price objective on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a research note on Thursday, March 20th. Finally, The Goldman Sachs Group started coverage on Syndax Pharmaceuticals in a report on Thursday, July 10th. They issued a "buy" rating and a $18.00 target price for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $34.10.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SNDX. Quarry LP acquired a new stake in Syndax Pharmaceuticals in the first quarter worth $25,000. Virtus ETF Advisers LLC increased its position in shares of Syndax Pharmaceuticals by 18.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock valued at $70,000 after buying an additional 827 shares in the last quarter. Magnetar Financial LLC bought a new position in Syndax Pharmaceuticals during the first quarter worth about $132,000. Optimize Financial Inc acquired a new position in Syndax Pharmaceuticals in the fourth quarter valued at about $152,000. Finally, Lazard Asset Management LLC bought a new stake in shares of Syndax Pharmaceuticals in the fourth quarter worth about $153,000.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.